CRISPR Therapeutics AG (CRSP) News
Filter CRSP News Items
CRSP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRSP News Highlights
- CRSP's 30 day story count now stands at 22.
- Over the past 19 days, CRSP's stories per day has been in a clear downtrend, falling by about 0.18 per day.
- The most mentioned tickers in articles about CRSP are DRUG, VRTX and GENE.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot UprisingIt’s time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs. |
3 Healthcare Technology Stocks to Improve Lives in 2024Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. |
Could CRISPR Therapeutics Stock Help You Become a Millionaire?There are plenty of reasons to be optimistic about CRISPR's future. |
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. |
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing TherapyShould you buy CRISPR's stock on the dip? |
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer StockThese stocks are currently going in different directions, but both could go up in a new bull market. |
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical ChiefThe fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. |
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No TomorrowCRISPR Therapeutics stock has increased in the double digits this year. |
3 Genomics Stocks to Unlock the Future of MedicineGenomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. |
Crispr Therapeutics Medical Chief Morrow to ResignThe gene editing company said the resignation wasn’t the result of any disagreement with the company. |